Plain language summary and patient perspective of the 2020 lung cancer screening recommendations by the US Preventive Services Task Force.

Screening low dose computed tomography lung cancer

Journal

Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629

Informations de publication

Date de publication:
20 Mar 2023
Historique:
entrez: 20 3 2023
pubmed: 21 3 2023
medline: 21 3 2023
Statut: aheadofprint

Résumé

This summary describes the research carried out by the United States Preventive Services Task Force (USPSTF for short) during a review and update of their lung cancer screening recommendations made in 2013. The USPSTF reviewed the results of clinical studies that used a type of scan called low dose computed tomography (LDCT for short). They wanted to see how successful LDCT was at finding lung cancers in people ho hadn't shown any physical signs of lung cancer, but had a history of smoking and were over 50 years of age. The review found that performing yearly LDCT scans in people who are at high risk of developing lung cancer is beneficial, as it means that some patients will be diagnosed earlier than they would be without this type of screening. People considered to be at high risk of developing lung cancer include: Adults aged 50 to 80 years who have smoked a pack of 20 cigarettes per day for 20 years or two packs per day for 10 years; OR Adults aged 50 to 80 years who currently smoke or have stopped smoking within the last 15 years. The information gained from reviewing the research enabled the USPSTF to update their lung cancer screening recommendations.

Identifiants

pubmed: 36935636
doi: 10.2217/fon-2022-1235
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Rachel Jenkins (R)

Future Science Group, London, UK.

Joanne Walker (J)

Becaris Publishing Ltd, Royston, UK.

Upal Basu Roy (UB)

LUNGevity Foundation, Chicago, IL, USA.

Jill Feldman (J)

Lung Cancer Patient & Advocate; Patient Author; Co-Founder EGFR Resisters.

Classifications MeSH